XBiotech Inc., a biopharmaceutical company, discovers, develops and markets True Human monoclonal antibodies for the treatment of various diseases. The company is headquartered in Austin, Texas.
| Revenue (TTM) | 300,000 |
| Gross Profit (TTM) | $3.36M |
| EBITDA | $-46.83M |
| Operating Margin | 0.00% |
| Return on Equity | -25.90% |
| Return on Assets | -18.80% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $4.60 |
| Price-to-Book | 0.52 |
| Price-to-Sales (TTM) | 12.23 |
| EV/Revenue | 24.05 |
| EV/EBITDA | -1.60 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -93.30% |
| Shares Outstanding | $30.49M |
| Float | $22.84M |
| % Insiders | 24.33% |
| % Institutions | 6.81% |
Volatility is currently expanding
IND Application for V-SPINE Study Completes 30-Day FDA Review Without Clinical Hold, Clearing Path for U.S. Patient Enrollment
